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a  b  s  t  r  a  c  t
Background:  The  COVID-19  pandemic  has  had  an  immeasurable  impact,  affecting  healthcare  systems,
the  global  economy,  and  society.  Exploration  of  trends  within  the  existing  COVID-19  data  may  guide
directions  for  further  study  and  novel  treatment  development.  As the  world  faces  COVID-19  disease,  it is
essential  to  study  its  epidemiological  and clinical  characteristics  further  to better  understand  and  aid  in
its detection  and  containment.
Methods:  We  aimed  to study  the  clinical  characteristics  of patients  infected  with  COVID-19  in Dubai,  a
multi-national  Society.
Results:  Our  findings  demonstrate  that during  the  first  wave of  the  COVID-19  epidemic,  age,  gender,  and
country  of  origin  were  associated  with  more  severe  cases  of COVID-19,  higher  risk for  hospitalization  and
death.  Male  individuals  between  41  and  60 years  of  age  from  India  had  the  most  significant  hospitalization
and  death  predictor  (p =  .0001).  The  predictors  for COVID-19  related  deaths  were  slightly  less  than  UAE
Nationals  by  individuals  from  GCC  (p =  .02)  that  were  followed  closely  behind  by  Pilipino  (p  = .02)  and
Arabs  (p =  .001).
Conclusion:  The  vulnerability  of  individuals  to  infection  and in  the  spectrum  of  COVID-19  symptoms
remains  to  be  understood.  There  are  large  variations  in  disease  severity,  one  component  of which  may  be
genetic  variability  in  responding  to  the  virus.  Genomics  of susceptibility  to COVID-19  infection  and  the
wide  variation  in  clinical  response  to COVID-19  in  patients  should  become  active  investigation  areas.
©  2021  The  Author(s).  Published  by  Elsevier  Ltd on  behalf  of  King  Saud  Bin  Abdulaziz  University  for
Health  Sciences.  This  is  an  open  access  article  under  the CC  BY-NC-ND  license  (http://creativecommons.
I
a
IntroductionHumanity faces extreme public health challenges in contem-
porary history when dealing with the disease caused by a new
type of coronavirus, called coronavirus disease 2019 – COVID-19.
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n early 2020, a novel coronavirus was isolated and named severe
cute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. The
orld Health Organization named the disease coronavirus disease
019 (COVID-19) and subsequently declared it a pandemic due to
he widespread infectivity and high contagion rate. The COVID-19
utbreak has become a pandemic threatening global health, under-
ining the global economy, and destabilizing societies across the
orld [2]. It has been well established that at the onset of the dis-
ase, the main manifestations of COVID-19 are fatigue, fever, dry
ough, myalgia, and dyspnea, with less typical symptoms being
asal congestion, headache, runny nose, sore throat, vomiting, and
iarrhea [3]. Severe patients often have dyspnea or hypoxemia one
eek after onset, after which septic shock, acute respiratory dis-
dulaziz University for Health Sciences. This is an open access article under the CC






















Fig. 1. Predictive margins of COVID-19 hospitaliza
tress syndrome (ARDS), difficult-to-correct metabolic acidosis, and
coagulation dysfunction develop rapidly. Of note, severe and criti-
cal patients can also present with a low fever, or even no apparent
fever, while mild patients show only low fever, mild fatigue, and no
pneumonia [4,5]. These asymptomatic or mild cases are challeng-
ing, as they can spread COVID-19 between individuals.
Although severe lung injury has been described at all ages, in
some high-risk individuals, such as the elderly or those affected by
multi-morbidities, the virus is more likely to cause severe intersti-
tial pneumonia, ARDS, and subsequent multi-organ failure, which
are responsible for severe acute respiratory failure and high death
rates [6]. It is now evident that not all infected patients develop
a severe respiratory illness; the reason for this is currently not
apparent. Moreover, very little is understood about inter-individual
genetic differences in the immune response to this virus.
Like global patterns, the number of confirmed cases in the
United Arab Emirates (UAE) has also increased. The UAE was
the first country in the Middle East to report a confirmed case,
announced on January 29, 2020, and linked to a family of Chinese
tourists traveling from Wuhan, China, the virus epicenter [7]. As of
November 9, 2020, the total number of confirmed cases has reached
142,143, according to the Ministry of Health and Prevention, with
a daily average increase of around 514 cases countrywide.
https://www.mohap.gov.ae/en/AwarenessCenter/Pages/
COVID19-Information-Center.aspx. UAE, and particularly Dubai, is
a society with a multi-ethnicity component. People from different
genetic backgrounds are living in the same geographic place. As the
world faces this new infectious disease, it is essential to study its
epidemiological and clinical characteristics further to understand
better why COVID-19 has different susceptibility and severity
on different individuals with dissimilar genetic backgrounds. An
enormous rush of research and studies is being published around
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ound to be short with this regard and still require more efforts
n that area as the burden of this disease continues to increase,
hich is why this study was  found to be of particular necessity
nd importance. In this study, we summarize and present the
pidemiological and clinical characteristics of COVID-19 positive
atients in the Emirate of Dubai, aiming to gain more information
o understand the prevalence, clinical manifestations better,
nd risk factors for COVID-19 severity and mortality in the UAE
ompared to the published global patterns.
ethods
tudy design and participants
This descriptive retrospective study was conducted on all
atients who attended primary healthcare centers in Dubai Health
uthority (DHA) from Feb 2020 to April 2020 and were diagnosed
ith COVID-19 (tested positive through Coronavirus PCR pharyn-
eal or nasopharyngeal swabs).
tudy procedure
Data was  recruited from DHA’s Electronic medical records
Salama).
tudy design (evaluation tools)
Demographic information, clinical characteristics, exposure
nformation, lab results, and Chest x-ray of each patient
ere collected, reviewed, and analyzed by different inde-
endent researchers. Both UAE citizens (UAE nationals) and
xpatriates were included in this study. The related data
ere double-checked and insert into the study tool indepen-
ently. Data that were missing were omitted. The severity of
Journal of Infection and Public Health 14 (2021) 886–891
Table 3
Clinical characteristics of the study population. DM:  Diabetes Mellitus, HTN: Hyper-
tension, CVD: CardioVascular Disease, CLD: Chronic Lung Disease, CKD: Chronic
Kidney Disease.
Clinical characteristics All patients (n = 2993)P atients with
symptoms (n = 1231)
Fever > 38c 816 (66)
Cough 673 (55)







Chest pain 44 (4)
Nausea or Vomiting 31 (3)
Chills 33 (3)
New olfactory/taste disorder 36 (3)
Diarrhea 31 (3)
Abdominal pain 25 (2)
Wheeze 4 (0.2)
Abnormal chest x-ray 139 (11)
Mechanical ventilation/intubation 7 (1)
Abnormal EKG 2 (0.1)
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COVID-19 was considered as per Dubai health authority guide-
line for COVID-19 https://www.dha.gov.ae/en/HealthRegulation/
Documents/National Guidelines of COVID 19 1st June 2020.pdf.
Data analysis and statistics
All collected data were entered into STATA version 15 (Stata-
Corp. 2017. Stata Statistical Software: Release 15. College Station,
TX: StataCorp LLC.) for statistical analysis. Descriptive statistics
were computed for the socio-demographic variables. The total clin-
ical data and outcome were determined using the Chi-square test,
and statistical significance was recorded for non-parametric data.
For all analyses, alpha (˛) was set at 0.05. A multiple regression
model was fitted to explore the possible predictors of COVID-19
symptoms, hospitalization, and death.
Ethics statement
The institutional review boards approved the Dubai Health
Authority Dubai (Approval # DSREC-06/2020 09). Aggregate
reporting of data assured to enhance confidentiality and accurate
reporting by the patient’s data. The investigators guaranteed the
anonymity of the data by coding the dataset.
Results
Overall, 37,716 COVID-19 tests were carried out in the
Dubai Health Authority from February to April 2020, out
of which 11,538 were positive. We  randomized our sam-
ple by simple randomization method using an online com-
puterized system: www.stattrek.com/statisctics/random-number-
generator.aspx#error. Medical data of 2993 COVID-19 patients
were then accessed, and almost the majority were diagnosed dur-
ing contact tracing of case-patients (1878, 63%). The majority of our
patients were between 18 and 40 years, male, non-UAE national,
residing in the UAE, non-healthcare workers (Table 1). Most of the
patients did not need hospitalization (2637, 88%) or Intensive care
unit (ICU) admission (2845, 95%), and only eight have died (Table 2).
Interestingly, most of our patients did not have any symptoms
(1601, 53%), and those with symptoms 987 (80%) had a resolution.
The most common symptoms on admission were fever (66%), cough
(55%), sore throat (35%), and headache (27%). Only 151 (12%) of the
2993 patients had dyspnea, and diarrhea was rather uncommon
(3%). Chest radiography showed no abnormality in 2854 (89%) of
the 2993 patients. only 313 (10%) of patients had comorbid condi-
tions, and only 1% had risky behavior such as smoking or drinking
alcohol (Table 3).
A multilinear regression model predicting COVID-19 hospi-
talization by age, gender, and country of origin was  statistically
significant (p < .001). We  calculated the predictive margins from the
linear regression model. Individuals between 41 and 60 years of age
(p = .000), males (p = .0001), and individuals from India (p = .0001)
had the most significant predictor of hospitalization (Fig. 1). A
multilinear regression model predicting death due to COVID-19
by age, gender, and country of origin was statistically significant
(p < .001). Individuals between 41 and 60 years of age had the most
significant predictor of death from COVID-19 infection (p < .001),
followed by ages 18–40 years of age (p = .001). Males were pre-
dicted to die from COVID-19 infection (p = .001) more than females
(Fig. 2). When analyzing the nationality correlations, individuals
from India that contracted COVID-19 were predicted to have the
highest death rate (p < .001); out of 6 death cases, three were from
India.
The predictors for COVID-19 related deaths were slightly less
than UAE Nationals by individuals from GCC (p = .025) that were
followed closely behind by Pilipino (p = .02) and Arabs (p = .001)
(Fig. 3). Individuals between 41 and 60 years of age (p = .001), males





888Fig. 2. Summary of death due to COVID-19 by age and gender is presented.
ignificant predictive margin of having symptoms than all other
ountries of origin (p = .001) had the most significant predictability
f having symptoms after COVID-19 infection (Fig. 4).
iscussion
The global health and economic consequences of the COVID-19
andemic are severe. It has been reported that progression into
ritical cases could happen within 3–10 days in 10%–20% of cases
8]. Although many therapies have been suggested, there are no
pecific options capable of treating COVID-19 disease or prevent-
ng SARS-CoV-2 infection. The only viable intervention and proven
o decrease the contagion rate seems to be strict quarantine mea-
ures for the general population. The possibility of a second wave of
ARS-CoV-2 infections is genuine; hence, preventive measures are
ssential. It is noteworthy that vaccines against the respiratory syn-
ytial virus (RSV), rhinoviruses, SARS-CoV-1, and MERS-CoV have
ot yet been successful. Thus, for SARS-CoV-2 (and these other
iruses), the medical and scientific communities must intensify
heir drug development studies to discover efficacious therapies
H.M. Farajallah et al. Journal of Infection and Public Health 14 (2021) 886–891
Table  1
Descriptive demographic characteristics of COVID-19 patients (n = 2993).
Variable, n(%)
Age (Years) ≤17 18–40 41–60 ≥61
197 (7) 1857 (62) 841 (28) 98 (3)
Gender  Male Female
2334 (78) 659 (22)
Nationality UAE Non-UAE
284 (9) 2709 (91)
UAE  residency Yes No Unknown/Missing
2724 (91) 147 (5) 122 (4)
Healthcare worker Yes No Unknown/Missing
63 (2) 2811 (94) 119 (4)
If  Healthcare worker, occupation Physician Nurse Unknown/Missing
3  (5) 5 (8) 55 (87)
Table 2
Clinical characteristics of COVID-19 patients (n = 2993).
Variable, n(%)
Case identification Clinical evaluation Routine surveillance Contact tracing of
case-patient
546 (18) 569 (19) 1878 (63)
Pregnancy Yes No Not Applicable (male or
women who are not
married)
Unknown/Missing
13 (0.4) 215 (7) 2593 (87) 172 (5.6)
Hospitalization Yes No Unknown/Missing
218 (7) 2637 (88) 138 (5)
ICU  admission during hospitalization Yes No Unknown/Missing
8 (0.3) 2845 (95) 140 (4.7)
Mechanical ventilation/Intubation Yes No Unknown/Missing
7 (0.2) 2833 (95) 153 (4.8)
Death Yes No Unknown/Missing
6 (0.2) 2916 (97) 71 (1.8)











29  (1) 1434 (48) 13 (0) 3 (0) 1514 (51)

















1231 (41) 1601 (53) 
Symptoms resolution Yes No 
987 (80) 4 (1) 
and preventive measures. Prevention would include avoidance of
viral contamination and possible identification of genetically sus-
ceptible subgroups within the human population.
Studies show that all age groups are susceptible to being infected
with COVID-19; however, most patients currently affected are
between 35 and 55 years [9]. The male gender has been shown
to hold a bigger share of COVID-19 infection, at 60% compared to
women [10]. Also, adult male patients with established comor-
bidities are more likely to be affected by the virus. Those most
significant were cardiovascular and cerebrovascular diseases, in
addition to diabetes. This phenomenon was attributed to the
weaker immune functions of these patients [7]. However, low over-
all comorbidities in infected patients in this study may  be due to
under-reporting and missing data. Our data showed that critical
cases consisted of around 0.3% of the COVID-19 patient population,
with a 30-day mortality of 0.2% (Table 2). The number of patients
admitted to the (Intensive Care Unit (ICU) was 8 (0.3%); of them,
7 (0.2%) required invasive mechanical ventilation, and 6 (0.2%)
had decreased. Therefore, predicting the likelihood of progression
to critical cases in non-critical cases and predicting in-hospital








tratified management of patients with COVID-19 in a circumstance
f the severe shortage of medical resources during the pandemic.
s a convenient and easy-to-detect index, age, nationality, and gen-
er must be obtained and monitored in all clinical settings and
atabases. Our study showed that individuals between 41 and 60
ears of age had the greatest predictability of death from COVID-19
nfection (p < .0001). Also, nationality and gender were both pre-
ictable for higher death, with Indians and males having the highest
ate (p < .0001 and p < .0001 consequently). This is predictable as
ost UAE laborers are from India, and they have low income and
ive in labor campuses. The campuses usually are crowded and
ocial distance is not followed as well. Our study shows 0.3% ICU
dmission, 0.3% ARDS, 4% pneumonia, and 0.2% rate for mechanical
entilation use and death.
UAE is trying its best to perform screening for at-risk individ-
als. To date, we  had more than 14,137,717 COVID-19 tests being
erformed, and 142,143 cases were diagnosed as positive; 1437.2
er 100k population. Recovery rate was 1398.2 per 100k popu-
ation and total death was  514; 5.2 per 100k population; with
ase Fatality Rate 0.4% (https://fcsa.gov.ae/en-us/Pages/Covid19/
AE-Covid-19-Updates.aspx). However, one of the major goals for
H.M. Farajallah et al. Journal of Infection and Public Health 14 (2021) 886–891
















Fig. 4. Predictive margins of having COVID-19 s
any healthcare service is to prevent death and severe morbidity.
It should be the first place people go for information, screening,
and testing for COVID-19, only turning to hospitals when neces-
sary. The case was the same in Dubai healthcare systems, as PHC
was the first station for the patients with COVID-19 symptoms.
There are no registered drugs to treat COVID-19 disease, and a
vaccine is not available [11,12]. Management is based mainly on
supportive therapy and treating the symptoms, and trying to pre-
vent respiratory failure. Several clinical trials of possible treatments
for COVID-19 are underway, based on antiviral, anti-inflammatory,
and immunomodulatory drugs, cell therapy, antioxidants, and
other therapies [13].
Large differences in outcomes for invasively ventilated patients
with COVID-19 have been reported for different countries – e.g.,
mortality rates for these patients in China [14] were reported to
be two times higher than those in Italy [15] and the USA [16]
and even within a single country, such as the UK [17]. Several




890ms by age and country of origin are presented.
ome people more vulnerable than others to SARS-CoV-2, influenc-
ng infection efficiency, the immune response to infection, or the
everity of COVID-19 symptoms [18–23]. Differences in outcomes
otivate urgent comparative research to characterize between-
ountry differences to inform best practice in the context of a surge
f cases. Since treatments and vaccines for COVID-19 have not
et been developed, strategies to contain the virus’s spread have
een implemented, such as encouraging social distancing and, in
he most affected regions, mandatory population confinement [24].
he main objective of adopting such measures is limiting the num-
er of infected people to a threshold at which the healthcare system
nd services can meet the demand, distributing the total number
f cases over time, a phenomenon that has been popularly called
attening the curve [25].The COVID-19 pandemic has had an immeasurable impact,
ffecting healthcare systems, the global economy, and society as
 whole. Exploration of trends within the existing COVID-19 data

















the  evidence. The Lancet 2020;395(10227):912–20.
[25] Kenyon C. Flattening-the-curve associated with reduced COVID-19 case fatalityH.M. Farajallah et al. 
opment. Our study demonstrates that men  in almost every age
group have higher test positivity, hospitalization, and death rates.
This finding mirrors data from over 50 countries across six conti-
nents in which death rates were more significant in men  versus
women, with an estimated 60% increased risk of severe illness or
death [26]. The differences in mortalities among the countries may
be explained by genomic variations of susceptibility to SARS-CoV-
2 infection and the differences in the prevalence of the comorbid
conditions of the patients and overwhelmed healthcare systems.
Conclusions
Our findings demonstrate that during the first wave of the
COVID-19 epidemic, age, gender, and country of origin were
associated with more severe cases of COVID-19, higher risk for
hospitalization and death. It is known that advanced age and pre-
existing comorbidities render a person more vulnerable to the
more severe health consequences of COVID-19. However, there
are large variations in disease severity, one component of which
may  be genetic variability in responding to the virus. We empha-
size that individuals’ vulnerability to infection and in the spectrum
of COVID-19 symptoms remain to be understood. Genomics of
susceptibility to SARS-CoV-2 infection and the wide variation in
clinical response to COVID-19 inpatients should become active
areas of investigation.
Limitation of study
Limitations of our study include the surveillance-based nature
of this evolving dataset. Some data was missing in our dataset, as
the study was conducted during a large-scale infectious disease
outbreak setting when the healthcare system was overwhelmed
by a large number of patients seeking medical care. Nevertheless,
given our study size, including population-level adjustments, we
can assume our findings are sufficiently powered, generalizable,
and externally valid. Although this study is a retrospective cohort
study in nature, the results could indicate the context measured.
Nevertheless, a more extensive national study with data from all







We  would like to thank all healthcare providers who sincerely
provided the care to the community during the COVID-19 crises.
[
891Journal of Infection and Public Health 14 (2021) 886–891
eferences
[1] Phelan AL, Katz R, Gostin LO. The novel coronavirus originating in Wuhan,
China: challenges for global health governance. JAMA 2020;323(8):709–10.
[2] Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? The Lancet
2020;395(10231):1225–8.
[3] Zhang J, Dong X, Cao Y, Yuan Y, Yang Y, Yan Y, et al. Clinical characteristics of
140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy (Copenhagen)
2020;75(7):1730–41.
[4] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of
patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet
2020;395(10223):497–506.
[5] Pan L, Mu M,  Yang P, Sun Y, Wang R, Yan J, et al. Clinical character-
istics of COVID-19 patients with digestive symptoms in Hubei, China: a
descriptive, cross-sectional, multicenter study. Am J Gastroenterol 2020
May;115(5):766–73.
[6] Lake MA.  What we know so far: COVID-19 current clinical knowledge and
research. Clin Med  2020;20(2):124–7.
[7] Chen N, Zhou M,  Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical
characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan,
China: a descriptive study. The Lancet 2020;395(10223):507–13.
[8] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hos-
pitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan,
China. JAMA 2020 March 17;323(11):1061–9.
[9] Adhikari SP, Meng S, Wu Y, Mao  Y, Ye R, Wang Q, et al. Epidemiology, causes,
clinical manifestation and diagnosis, prevention and control of coronavirus dis-
ease (COVID-19) during the early outbreak period: a scoping review. Infect Dis
Poverty 2020;9(1):29.
10] Li L, Huang T, Wang Y, Wang Z, Liang Y, Huang T, et al. 2019 novel coro-
navirus patients’ clinical characteristics, discharge rate and fatality rate of
meta-analysis. J Med  Virol 2020.
11] Prompetchara E, Ketley C, Palaga T. Immune responses in COVID-19 and poten-
tial vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy
Immunol 2020;38(1):1–9.
12] Shanmugaraj B, Malla A, Phoolcharoen W.  Emergence of novel coronavirus
2019-nCoV: need for rapid vaccine and biologics development. Pathogens
(Basel) 2020;9(2):148.
13] Zhang T, He Y, Xu W,  Ma  A, Yang Y, Xu K. Clinical trials for the treatment of
Coronavirus disease 2019 (COVID-19): A rapid response to urgent need. Sci
China Life Sci 2020 May;63(5):774–6.
14] Guan W,  Ni Z, Hu Y, Liang W,  Ou C, He J, et al. Clinical characteristics of coro-
navirus disease 2019 in China. N Engl J Med  2020;382(18):1708–20.
15] Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Base-
line  characteristics and outcomes of 1591 patients infected with SARS-CoV-2
admitted to ICUs of the Lombardy Region, Italy. JAMA 2020;323(16):1574–81.
16] Auld S, Caridi-Scheible M,  Blum J, Robichaux C, Kraft C, Jacob J, et al. ICU and
ventilator mortality among critically ill adults with coronavirus disease 2019.
Crit Care Med  2020;48(9):e799–804.
17] Qian Z, Alaa AM,  van der Schaar M,  Ercole A. Between-centre differences
for  COVID-19 ICU mortality from early data in England. Intens Care Med
2020;46(9):1779–80.
18] Cao Y, et al. Comparative genetic analysis of the novel coronavirus
(2019nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discov
2020;6:11.
19] Hussain M, et al. Structural variations in human ACE2 may  influence its binding
with SARS-CoV-2 spike protein. J Med  Virol 2020.
20] Walls AC, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike
glycoprotein. Cell 2020.
21] Hoffmann M,  et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and
is  blocked by a clinically proven protease inhibitor. Cell 2020.
22] Luostari K, et al. Type II transmembrane serine protease gene variants associate
with breast cancer. PLoS One 2014;9:e102519.
23] Schrode N, et al. Synergistic effects of common schizophrenia risk variants. Nat
Genet 2019;51:1475–85.
24] Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, et al.
The psychological impact of quarantine and how to reduce it: rapid review ofrates – an ecological analysis of 65 countries. J Infect 2020;81(1):e98–9.
26] Rozenberg S, Vandromme J, Martin C. Are we equal in adversity? Does Covid-19
affect women and men  differently? Maturitas 2020;138:62–8.
